Combination of antifungal agent and prebiotic for acute vulvovaginal candidiasis
Aim: To assess efficacy and safety of Ecofucin® vaginal suppositories based on the time to clinical and microbiological remission in women with acute vaginal or vulvovaginal candidiasis. Patients and Methods: The study enrolled women aged 18-45 with acute vaginal or vulvovaginal candidiasis. All patients were subdivided into 2 groups. Study group included 36 patients who received Ecofucin® vaginal suppositories (natamycin 100 mg plus lactulose 300 mg) once a day for 6 days. Control group included 36 patients who received Pimafucin® vaginal suppositories (natamycin 100 mg) once a day for 6 days. Efficacy and safety of medications were assessed by gynecological examination, laboratory tests, and patient diaries. Follow-up examinations were performed at days 4, 7, and 37 (±2 days) after treatment begins (30±2 days after treatment finishes). Results: Combination of antifungal medication (natamycin) and prebiotic in a vaginal suppository provides more rapid clinical remission and complete elimination of VVC causative agent thus resulting in active growth of lactobacilli, principal competitors of yeasts in vaginal microbiocoenosis. Conclusions: Good tolerability of Ecofucin® was demonstrated, no adverse reactions were reported.